Breast Cancer ER+ PR- & HER2 +

her
Please Visit and Join the WeHeal ER+ PR- HER2+ Breast Cancer Community

Information and References: John Hopkins University | Susan G. Komen

Patient Resources and Related Organizations: breastcancer.org | Nature.com

News and Media: News-Medical.net

Clinical trials: Clinicaltrials.gov | EU Clinical Trials Register | WeHeal Guide to Researching Clinical Trials

Search Clinical Trials

A cancer is called estrogen-receptor-positive (or ER+) if it has receptors for estrogen. This suggests that the cancer cells, like normal breast cells, may receive signals from estrogen that could promote their growth. The cancer is progesterone-receptor-positive (PR+) if it has progesterone receptors. Again, this means that the cancer cells may receive signals from progesterone that could promote their growth. Roughly two out of every three breast cancers test positive for hormone receptors.

Testing for hormone receptors is important because the results help you and your doctor decide whether the cancer is likely to respond to hormonal therapy or other treatments. Hormonal therapy includes medications that either (1) lower the amount of estrogen in your body or (2) block estrogen from supporting the growth and function of breast cells. If the breast cancer cells have hormone receptors, then these medications could help to slow or even stop their growth. If the cancer is hormone-receptor-negative (no receptors are present), then hormonal therapy is unlikely to work. You and your doctor will then choose other kinds of treatment.

Please Visit and Join the WeHeal ER+ PR- HER2+ Breast Cancer Community


WeHeal is very grateful to our valued sources of information which include Wikipedia, WebMD, ClinicalTrials.gov, Cancer.gov, Infoplease, and the US CDC (Center for Disease Control).